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Abstract
Background: Although perineural invasion is a well known prognostic factor used in
several cancers, its prognostic role in esophageal squamous cell carcinoma remains
controversial. Here, we investigated the prognostic role of perineural invasion in surgi-
cally treated esophageal squamous cell carcinoma.
Methods: We retrospectively reviewed the medical records of 316 patients who under-
went esophagectomy and lymph node dissection for esophageal squamous cell carci-
noma between 2007 and 2016.
Results: Overall, 287 men (mean age: 62.73  7.97 years) were included in the study.
The median follow-up period was 35.97  30.99 months, perineural invasion was
confirmed in 25 patients, and three-year overall and disease-free survival were signifi-
cantly lower in the perineural invasion group than in the no-perineural invasion
group (75.9% vs. 40.0%, p < 0.001; 70.3% vs. 21.6%, p < 0.001). Cumulative incidences
of locoregional recurrence and distant metastasis over three years were higher in the
perineural invasion group (13.8% vs. 9.6%, p = 0.009 and 52.8% vs. 14.6%, p < 0.001).
On performing multivariable analysis, perineural invasion, pathological stage, incom-
plete resection, and neoadjuvant therapy were adverse risk factors for disease-free sur-
vival. The concordance index increased when perineural invasion was included in the
model (0.712 vs. 0.723). On subgroup analysis, perineural invasion demonstrated a
prognostic value in node-negative patients (79.4% vs. 35.7%, p = 0.012).
Conclusions: Perineural invasion was found to be an adverse risk factor for disease-
free survival in surgically treated patients with esophageal squamous cell carcinoma.
Close observation and individualized adjuvant therapy may be helpful for patients
with perineural invasion.
K E YWORD S
esophageal squamous cell carcinoma, perineural invasion, prognosis
INTRODUCTION
Esophageal cancer is one of the most invasive cancers world-
wide, with the highest incidence rates found in Eastern Asia
and Southern and Eastern Africa.1 The dominant type of
esophageal cancer in Eastern Asia is esophageal squamous
cell carcinoma (ESCC). Despite recent improvements in
diagnostic and therapeutic modalities, its prognosis remains
poor, with an overall survival rate of 15%–25% and a high
risk of metastases and recurrence.2,3 Prognostication of
ESCC using the Tumor, Node and Metastasis (TNM) classi-
fication system of the American Joint Committee on Cancer
is widely accepted.4 Although the TNM system can provide
a satisfactory prediction of survival, its accuracy is variable;
for example, even for superficial tumors, ESCC showed sig-
nificant rates of metastases and recurrences, which is related
to poor outcomes.3,5 Therefore, identifying new prognostic
factors for ESCC in addition to the current staging system is
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important for optimizing treatment and improving
outcomes.
Esophageal cancer cells spread through direct infiltration
of vascular or lymphatic channels. This pattern of invasion
is well characterized and precedes metastases and disease
recurrence in ESCC. In addition to these metastatic routes,
perineural invasion (PNI) can occur, which is the neoplastic
invasion of nerve cells. 6,7 PNI is most commonly reported
in head and neck cancers, with an incidence as high as 80%;
it is considered a significant risk factor for invasion and
metastasis and is therefore regarded as a negative prognostic
factor.8 However, the significance of PNI in ESCC remains
controversial; while some studies suggest that PNI status is
related to a poor prognosis in ESCC, others question its role
as a predictor of prognosis.6,9–11 Therefore, this retrospective
study investigated the prognostic effect of PNI in surgically
treated ESCC patients. We present the following article in
accordance with the STROBE reporting checklist.
METHODS
Patients
We retrospectively reviewed the medical records of patients
with ESCC who were surgically treated between January
2007 and December 2016. Patients with operative mortality
(n = 15) and who underwent a procedure with noncurative
intent (n = 12) were excluded. A total of 316 patients under-
went esophagectomy and lymph node dissection for thoracic
ESCC. The clinicopathological data of the patients were
recorded in a prospectively established institutional data-
base. This study was approved by the Institutional Review
Board of Yonsei University College of Medicine (IRB No: 4–
2020-0770). The requirement to obtain informed consent
was waived owing to the retrospective nature of the study by
the aforementioned Institutional Review Board.
Preoperative endoscopic biopsy confirmed histological
diagnosis. The staging workup consisted of ultrasonography,
chest and abdominopelvic computed tomography (CT), and
positron emission tomography. The lymph node
(LN) station was utilized by the 11th Japanese Guidelines
for Clinical Pathological Studies on Carcinoma of the
Esophagus.12 After the workup, patients with locally
advanced cancers (T3 or T4a) or multiple LN metastases
were assigned to neoadjuvant chemoradiation or chemo-
therapy following institutional policy. Upfront McKeown
transthoracic esophagectomy was performed for clinically
resectable T1N1–2 ESCC following institutional guidelines.
Total mediastinal lymphadenectomy comprising dis-
section of bilateral recurrent laryngeal nerve nodes was rou-
tinely performed, except for patients with significant
comorbidities. For a minimally invasive approach,
thoracoscopic or robot-assisted esophagectomies were per-
formed. Bilateral neck dissection under the collar incision
was performed in patients with upper esophageal cancer,
and with middle or lower esophageal cancer when clinically
evident metastases at the upper mediastinum or cervical
area were suspected. Usually, a gastric tube was used to
reconstruct the esophagus. Gastric mobilization and upper
abdominal LN dissection were performed using a laparo-
scopic or laparotomy approach based on the surgeon’s pref-
erences. Esophagogastrostomy was performed with a
circular stapler for intrathoracic anastomoses, and circular
stapling or the two-layered hand-sewn method was
employed for cervical anastomoses.
Chest and abdominopelvic CT scans were obtained post-
operatively at six-month intervals to detect recurrence.
Locoregional recurrence was defined as disease occurring at
the anastomosis site, or at sites where LN dissection had
been performed. Distant recurrence was defined as recur-
rence outside the operative field, such as the lung, brain,
liver, and bone. Recurrence was confirmed on tissue biopsy
if clinically indicated.
Pathological evaluation
Histopathological slides were reviewed by an expert patholo-
gist in esophageal cancer from our institution who was
blinded to postoperative outcome and prognosis. Specimens
were stained with hematoxylin and eosin (H&E), and the
presence of PNI was carefully examined. When viable tumor
cells were identified within any of the three layers of the
nerve sheath, PNI was considered to be present. In cases
where tumor cells were not located within the nerve sheath
but close to the perineural environment, the criterion for
PNI diagnosis included involvement of tumor cells around
≥33% of the nerve circumference (Figure 1(a) and (b)). 8,13
Statistical analysis
Clinicopathological parameters are described as means 
standard deviations for continuous variables and as frequen-
cies (%) for categorical variables. Student’s t-test, chi-square,
or Fisher’s exact tests were applied for the assessment of
differences between groups. Overall survival (OS) was
estimated from the date of surgery to the date of the last
follow-up or death from any cause. Disease-free survival
(DFS) extended from the day of surgery to the date of the
first recurrence, last follow-up, or death. We applied the
Kaplan–Meier method to analyze survival rates and cumula-
tive hazard. Risk factors were analyzed using logistic regres-
sion analysis. Because of concern for multicollinearity, we
calculated variance inflation factors (VIFs) among potential
predictors.14 Following the survival and risk factor analysis,
we calculated Harrell’s concordance index for two separate
models to determine the explanatory ability of PNI; model
1 without PNI and model 2 with PNI. A p-value of <0.05
was considered statistically significant. Statistical analysis
was performed using SPSS (ver.25.0; IBM Corp.), R version
4.0.2 (R Foundation for Statistical Computing), and STATA
(ver.15.0; STATA Corp.).
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RESULTS
Patient demographics
The patient demographics are presented in Table 1. The
mean age was 62.73  7.97 years, and 287 (90.8%) patients
were male, while 70 (22.2%) underwent neoadjuvant ther-
apy. Most patients (93.4%) had SCC in the middle or lower
esophagus, and 51.8% presented with clinical stages 0 or
1 of the disease. R0 resection was achieved in 306 patients
(96.8%); the mean number of dissected LNs was
48.93  26.89; PNI was identified in 25 (7.9%) patients.
Correlation between perineural invasion and
pathological features
The pathological features with and without PNI are pres-
ented in Table 2. The clinical stage tended to be higher in
the PNI group, with 88% of patients presenting with patho-
logical T stage of ≥3 compared to the 45% of patients in the
no-PNI group (p < 0.001). LN metastases were confirmed in
72% in the PNI group when compared to 35.8% of patients
in the no-PNI group (p = 0.001). There was no difference
observed in the tumor differentiation between both groups.
Survival and recurrence pattern
The median follow-up period was 35.97  30.99 months.
The three-year OS and DFS of all patients were 73.5% and
66.4%, respectively (Figure 2(a) and (b)). The three-year OS
and DFS were significantly lower in the PNI group (75.9%
vs. 40.0%, p < 0.001; 70.3% vs. 21.6%, p < 0.001) (Figure 2
(c) and (d)).
Recurrence of ESCC was detected in 80 (25.3%) of the
316 patients; locoregional recurrence occurred in 44 (13.9%)
TAB L E 1 Patient demographics
Variable Value
Age (years) 62.73  7.97





Tumor differentiation (n, %)
Well differentiated (G1) 43 (13.6%)
Moderately differentiated (G2) 179 (56.7%)
Poorly differentiated (G3) 94 (29.7%)
Neoadjuvant treatment (n, %) 70 (22.2%)
Three-field dissection (n, %) 20 (6.3%)
R0 resection (n, %) 306 (96.8%)
Number of total dissected lymph nodes (n) 48.93  26.89
Depth of invasion (T stage) (n, %)









Pathological stage (n, %)
0 and I 164 (51.8%)
II 83 (26.3%)
III 69 (21.9%)
Perineural invasion (n, %) 25 (7.9%)
Note: Data are shown as either mean  standard deviation, or as n (%).
F I G U R E 1 The presence of perineural invasion in an esophageal
squamous cell carcinoma specimen stained with hematoxylin and eosin.
(a) The nerve fiber was partially surrounded by tumor cells (red arrow).
(b) Tumor cells embedded in the perineurium (black arrow)
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and distant metastases occurred in 45 (14.2%) patients. Nine
patients (2.8%) had recurrence at multiple sites
(locoregional and/or distant recurrence). The most common
site of locoregional recurrence was the mediastinal LNs
(4.7%) followed by the cervical LNs (4.1%). The liver (3.2%)
was the most common site of distant metastases followed by
the lungs (2.8%). In the no-PNI group, locoregional recur-
rence was observed in 31 (10.7%) patients. Recurrence at an
adjacent LN occurred in 27 patients, and recurrence at the
anastomosis site was observed in two patients. Distant
metastasis was observed in 35 (12.0%) patients in the no-
PNI group. A total of 13 patients had liver metastasis, while
11 showed lung metastasis, and seven patients showed bone
metastasis. Distant LN metastasis was observed in
11 patients. In the PNI group, locoregional recurrence was
observed in four patients (16%). Among them, three showed
recurrence at the mediastinal LNs and one showed recurrence at
the anastomosis site. A total of 10 patients (40%) in the PNI
group had distant metastases. Three showed metastases at an
upper abdominal LN (No.16), two presented with multiple lung
metastases, two showed bone metastases, and two had metastases
in abdominal organs such as the liver and colon.
Figure 3 shows cumulative incidence curves of
locoregional recurrence and distant metastasis of the











1 214 (72.6%) 2 (8.0%)
2 32 (12.0%) 1 (4.0%)
3 43 (14.8%) 21 (84.0%)
4 2 (0.6%) 1 (4.0%)
Nodal metastases 0.001
Absent 187 (64.2%) 7 (28%)








163 (56.1%) 16 (64%)
Poorly differentiated
(G3)
86 (29.5%) 8 (32%)
Note: Data are shown as n (%).
F I G U R E 2 Survival curves showing the (a) overall survival (OS) and (b) disease-free survival (DFS) of the entire sample. Survival curves showing (c) OS
and (d) DFS according to perineural invasion
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no-PNI and PNI groups. The cumulative incidences of
locoregional recurrence over the three-year period were
9.6% in the no-PNI and 18.3% in the PNI group (p = 0.009,
Figure 3(a)), and the cumulative incidences of distant metas-
tases over the three-year period were 14.6% in the no-PNI
and 52.8% in the PNI group (p < 0.001, Figure 3(b)).
Risk factors for disease-free survival
Age, neoadjuvant therapy, incomplete resection, stage III,
and PNI were risk factors for DFS on the univariable analy-
sis (Table 3). We performed the multivariable analysis with
two models, model 1 without PNI and model 2 with PNI.
The multivariable analysis of model 2 showed neoadjuvant
therapy (hazard ratio [HR]: 2.436, 95% confidence interval
(CI): 1.589–3.735, p < 0.001), incomplete resection (HR:
2.114, 95% CI: 1.166–3.835, p = 0.014), stage III (HR: 4.987,
95% CI: 3.114–7.987, p < 0.001), and PNI (HR: 1.890, 95%
CI: 1.088–3.282, p = 0.024) as risk factors for DFS. The VIFs
of the predictors mentioned above varied from 1.008–1.164,
suggesting no collinearity in both models. The concordance
index was calculated for each model. The concordance indi-
ces for models 1 and 2 were 0.712 (95% CI: 0.638–0.786)
and 0.723 (95% CI: 0.649–0.798), respectively. Model
2 appeared to have a better prognostic ability with a slightly
increased concordance index.
Subgroup analysis
Subgroup analysis was performed to determine the prognos-
tic role of PNI in specific situations. The three-year DFS was
significantly lower in the PNI group in patients with and
without LN metastasis (Figure 4(a) and (b)). The three-year
DFS of the PNI group was 35.7% and that of the no-PNI
group was 79.3% (p = 0.012) in the subgroup of node-
negative patients. The three-year DFS of patients with
grades 1 and 2 tumor differentiation was significantly lower
in the PNI group (29.9% vs. 72.5%, p < 0.001) (Figure 4
(c) and (d)). Among patients with grade 3 differentiated
tumors, the three-year DFS was also lower in the PNI group
(0% vs. 64.8%, p < 0.001). We also conducted subgroup
analysis according to neoadjuvant treatment and found that
F I G U R E 3 Cumulative incidence curves of recurrence showing (a) locoregional recurrence and (b) distant metastases
T A B L E 3 Risk factors for three-year disease-free survival
Multivariate analysis
Univariate analysis
Model 1 Model 2, PNI
Hazard ratio (95% CI) p Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age 1.008 (0.983–1.033) 0.551 1.024 (0.991–1.058) 0.163 1.011 (0.988–1.035) 0.339
Sex 0.772 (0.376–1.586) 0.481 0.858 (0.339–2.175) 0.747 0.777 (0.377–1.603) 0.495
Neoadjuvant Tx. 2.037 (1.346–3.083) 0.001 0.741 (0.382–1.435) 0.373 2.436 (1.589–3.735) < 0.001
Incomplete resection 4.467 (2.614–7.631) < 0.001 1.167 (0.476–2.858) 0.020 2.114 (1.166–3.835) 0.014
Stage II (vs. 0 and I) 1.553 (0.937–2.573) 0.087 0.736 (0.329–1.647) 0.456 1.489 (0.896–2.474) 0.124
Stage III (vs. 0 and I) 5.736 (3.689–8.918) < 0.001 3.860 (1.620–9.193) 0.002 4.987 (3.114–7.987) < 0.001
Perineural invasion 4.000 (2.393–6.688) < 0.001 1.890 (1.088–3.282) 0.024
Concordance index 0.712 (0.638–0.786) 0.723 (0.649–0.798)
Abbreviations: CI, confidence interval; PNI, perineural invasion.
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the 3-year DFS was lower in the PNI group (Figure 4(e) and
(f)). PNI presence was related to DFS regardless of nodal
status, tumor differentiation, and neoadjuvant therapy.
DISCUSSION
Our retrospective analysis revealed that PNI following
esophageal cancer surgery correlated with aggressive fea-
tures, such as higher T stage and LN metastasis, and was an
unfavorable prognostic factor for DFS.
Our findings were consistent with those of previous
studies on the clinical implications of PNI. Chen et al. ana-
lyzed 430 patients with ESCC and reported that PNI can be
an independent prognostic factor and that PNI status in pri-
mary ESCC should be considered for therapy stratification. 6
Guo et al. also analyzed 162 patients with pN0M0 ESCC
and concluded that PNI is an important risk factor to deter-
mine outcomes and that it can be used for risk assessment
and to tailor adjuvant radiotherapy.15 Our data also showed
poor survival in patients with PNI, including in node-
negative patients (Figure 4(a)); hence, it could be an
F I G U R E 4 Survival curves of disease-free survival showing (a) node-negative patients, (b) node-positive patients, (c) tumor differentiation grade 1 and
2, (d) grade 3, (e) patients who underwent neoadjuvant treatment, and (f) those who did not undergo neoadjuvant treatment
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indicator for adjuvant therapy. The latest National Compre-
hensive Cancer Network guidelines do not recommend
adjuvant treatment for ESCC with PNI,16 whereas in head
and neck cancer, PNI is usually regarded as an indicator for
adjuvant radiotherapy.17 Notably, the cumulative incidences
of both locoregional recurrence and distant metastasis over
three years were higher in the PNI group, meaning that
PNI was related to both locoregional and distant failures.
Although Guo et al. reported that PNI could be an indica-
tor for adjuvant radiotherapy,15 we considered that both
adjuvant chemotherapy for distant metastasis and adju-
vant radiotherapy for local control may be beneficial for
patients with PNI. The appropriate modality of adjuvant
therapy should be studied in further analyses. Another
strength of this study is its statistical analysis. We calcu-
lated the concordance index of two multivariable models
and showed that the inclusion of PNI increased the con-
cordance index, which indicates the predictive ability of a
survival model.18,19 Therefore, combining PNI with the
TNM staging system could increase the accuracy of sur-
vival prediction.
Although the importance of PNI is evident, its definition
and detection in ESCC have not been uniformly established.
In our study, PNI was observed in 7.9% of ESCC patients
who underwent surgery, whereas other studies have reported
incidences ranging from 22.2%–48.3%.20 These differences
in its incidence may have originated from the absence of
standardized detection methods for PNI in ESCC. Detecting
PNI with H&E staining is difficult if the nerve fibers are
damaged by invading tumor cells or if the nerve fibers are
extremely thin.9 Thus, other methods, such as keratin or
S-100 protein detection, which has been implicated in colo-
rectal carcinogenesis, may improve the accuracy of PNI
detection.21 When reporting the pathology of head and neck
cancer, the presence of PNI is usually documented;20,22,23
however, we suggest that it should also be documented
for ESCC.
The metastatic mechanism of PNI has been explained in
several ways. PNI is not an extension of lymphovascular
metastasis because lymphatics do not penetrate the inner
layer of the nerve sheath.24 Recently, reciprocal signaling
between tumor cells and nerves were reported in vitro.7,9,13
The receptors for nerve growth factors (NGFs) such as
NTRK1 and NGFR are expressed on nerves, while NGF pro-
duction in esophageal cancer cells is shown in vitro; further,
esophageal cancer cells may induce neurite outgrowth of
neuronal cells.2 In these biological processes, neurotransmit-
ters and neuropeptides secreted by nerves act as molecular
determinants and promote invasion and metastasis.25 PNI
comprises both infiltration and invasion of tumor cells
towards nerve sheaths and a dynamic signaling process for
metastases. As a result, PNI correlated with poor pathologic
features, showing that PNI reflects a more malignant behav-
ior in ESCC.
This study has certain limitations. First, this was a
retrospective study carried out at a single institution, with a
relatively small number of patients and a short period of
follow-up. Future studies should enroll a larger number of
patients who are followed-up over a longer period. Second,
the guidelines for detecting PNI in ESCC are yet to be stan-
dardized. We did not perform immunohistochemical
staining, such as anti-S-100, to detect nerve fibers that could
improve the accuracy of PNI detection.8 The low incidence
of PNI in this study may be explained by underestimation
owing to a lack of precise protocols.
In conclusion, PNI was an independent prognostic
factor for shorter DFS in patients with surgically treated
ESCC as assessed by multivariable analyses. The prognos-
tic effect of PNI was not affected by nodal status, tumor
differentiation, or neoadjuvant treatment. Given the prog-
nostic implications of the PNI status, it should be clearly
documented on the pathologic report to identify patients
who require a closer follow-up. Additionally, PNI could
also be an important indicator for postoperative adjuvant
therapy.
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